Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks
Gilead is riding the success of HIV med Biktarvy as its HIV portfolio and overall sales dwindle. (Gilead)
Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light with growth nearly quadrupling in the last year. Hoping to capitalize on its next-gen HIV portfolio's success, Gilead it touting new data for Biktarvy and Truvada follow-up Descovy that could help pad their cases.
Biktarvy measured up to two treatment regimens, including archrival ViiV Healthcare's Tivicay, in suppressing symptoms of HIV in newly treated patients at the 144-week mark, according to data from two phase 3 clinical trials released Wednesday.
Gilead said in a statement the two studies helped reinforce Biktarvy's strength in newly diagnosed patients.
From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx
THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!
The drug once again showed it's "an effective treatment that offers durable viral suppression and maintains a high barrier to resistance,” said Diana Brainard, Gilead's senior VP for HIV and emerging viruses. “These longer-term data reaffirm Biktarvy’s role as a first-line treatment option.”